Prostate Cancer Diagnostic FC303 Gets Domestic Approval, Improved Earnings and Pipeline Progress

Prostate cancer diagnostic FC303 (Prostavue) received domestic marketing approval in April 2026, launch imminent
Prostate cancer therapeutic FC705 in phase 3 in Korea and phase 2a in the US
Consolidated Q1 2026 revenue up 25% YoY to 63.6 billion won, net loss narrowed
Cash and cash equivalents at 7.1 billion won, up from 4.3 billion won at year-end 2025
Global licensing deals for FC303 in Europe, China, Turkey, etc.
R&D expenses of 2.1 billion won (32% of sales), continued pipeline investment